Ubs Oconnor LLC Aura Biosciences, Inc. Transaction History

Ubs Oconnor LLC

$1.46 Billion
Q3 2024

A detailed history of Ubs Oconnor LLC transactions in Aura Biosciences, Inc. stock. As of the latest transaction made, Ubs Oconnor LLC holds 106,898 shares of AURA stock, worth $950,323. This represents 0.07% of its overall portfolio holdings.

Number of Shares

106,898

Holding current value

$950,323

% of portfolio

0.07%

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$6.9 - $10.36 $112,325 - $168,650	16,279 Added 17.96%	106,898 $952,000
Q2 2024 Aug 14, 2024	BUY	$6.81 - $7.89 $158,632 - $183,789	23,294 Added 34.6%	90,619 $685,000
Q1 2024 May 15, 2024	SELL	$7.09 - $9.24 $160,765 - $209,517	-22,675 Reduced 25.19%	67,325 $528,000
Q4 2023 Feb 14, 2024	BUY	$7.02 - $11.98 $322,920 - $551,080	46,000 Added 104.55%	90,000 $797,000
Q2 2023 Aug 14, 2023	BUY	$8.51 - $13.33 $374,440 - $586,520	44,000 New	44,000 $543 Million
Q3 2022 Nov 14, 2022	SELL	$13.1 - $20.34 $1.02 Million - $1.59 Million	-78,109 Reduced 86.27%	12,430 $225 Million
Q2 2022 Aug 12, 2022	BUY	$12.37 - $21.86 $513,837 - $908,042	41,539 Added 84.77%	90,539 $1.28 Million
Q1 2022 May 16, 2022	BUY	$15.94 - $23.34 $781,060 - $1.14 Million	49,000 New	49,000 $1.08 Million

Others Institutions Holding AURA

# of Institutions

Shares Held

37.6M

Call Options Held

122K

Put Options Held

38.5K

Matrix Capital Management Company, LP Waltham, MA

6.92M
Shares

$61.5 Million
2.94% of portfolio
Eventide Asset Management, LLC Boston, MA

5.8M
Shares

$51.6 Million
0.91% of portfolio
Adage Capital Partners Gp, L.L.C. Boston, MA

4.88M
Shares

$43.4 Million
0.08% of portfolio
Medicxi Ventures Management (Jersey) LTD

3.04M
Shares

$27 Million
5.63% of portfolio
Black Rock Inc. New York, NY

3.01M
Shares

$26.7 Million
0.0% of portfolio

View Full List

About Aura Biosciences, Inc.

Ticker AURA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,273,600
Market Cap $260M
Description
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develop...

More about AURA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Oconnor LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Oconnor LLC with notifications on news.

Account